Anpario PLC (AIM: ANP) has just completed a £3.0m share buyback, is a week away from publishing interim results, and has told shareholders that early 2026 trading was running in line with full-year consensus after a record 2025. Yet the UK-based maker of natural animal feed additives still carries a Market Value of only around £107m, and its shares, at 535p on 2 September 2026, sit below the 570p top of their 52-week range.

The key question is whether the interim results due on 9 September 2026 confirm that last year's step-change in revenue, margins and profit was the start of a durable trend rather than a one-off lift from the Bio-Vet acquisition.

AGM statement, completed buyback and a board vacancy

The most recent commercial update came with the AGM statement on 18 June 2026. Chairman Matthew Robinson reported a strong start to 2026, with Revenue and profit ahead of the prior year and aligned with full-year analyst consensus, which the company cited as revenue of £50.3m, adjusted EBITDA of £10.3m and net cash of £16.9m. The Middle East traded particularly strongly, including first sales of the newly launched lysophospholipid additive AmpLIPhy, the US grew across both the Bio-Vet and Anpario (LSE:ANP) ranges, and Australasia maintained its pace of growth.

Higher logistics costs were absorbed and then passed on, and raw-material Inflation in acid-based eubiotic products, roughly 20% of sales, was met with disciplined price rises. First-half gross margins were said to be consistent with the second half of 2025. Cash stood at £10.9m at 31 May 2026, after £2.0m of Buybacks and the prior-year dividend.

On 27 July 2026 the company confirmed completion of the buyback launched on 27 April, having repurchased 556,803 shares for £3.0m at an average of 538.79p and cancelled them, leaving 20,039,026 shares in issue. The board said the programme reflected "continued confidence in the Company's future prospects".

The latest announcement, on 17 August 2026, was sadder: Tim Pollock, a non-executive director since August 2023 and chairman of the remuneration committee, died. The board is reviewing the appointment of additional non-executive directors in line with the QCA Corporate Governance Code.

What Anpario does

Anpario (LSE:ANP) is an independent international manufacturer and distributor of natural feed additives for animal health, nutrition and biosecurity. It manufactures in the United Kingdom and sells through subsidiaries and distributors in more than 80 countries to livestock producers, including pig and dairy farmers.

Core brands include Orego-Stim, an oregano-based phytogenic, Optomega Algae, an omega-3 supplement, pHorce, an acid-based eubiotic used for feed hygiene, and the Credence water-sanitising tablet. The Acquisition of US-based Bio-Vet on 30 September 2024 for £5.8m added a dairy and ruminant-focused range, including the QuadriCal calcium bolus, and a much larger North American footprint.

The company makes money by selling higher-value branded additives that improve animal performance and reduce reliance on antibiotics, and growth in premium lines has flowed through to margins. Asia was the largest region in 2025 at 34% of group sales, with the Americas at 23%.

FY2025 results: revenue up 24%, profit before tax up 54%

Final results for the year to 31 December 2025, published on 31 March 2026, were the strongest in the company's recent history. Revenue rose 24% to £47.2m from £38.2m, with like-for-like sales excluding Bio-Vet up 12% to £40.5m. Bio-Vet contributed £6.7m in its first full year.

Gross profit increased 34% to £24.0m and gross Margin widened to 50.9% from 46.9%, helped by the shift towards premium products. Adjusted EBITDA climbed 38% to £9.6m, and profit before tax rose 54% to £8.0m from £5.2m. Basic Earnings Per Share jumped 63% to 40.20p, while diluted adjusted EPS rose 33% to 39.49p.

Cash ended the year at £12.4m, up from £10.5m, even after paying the final £0.8m of Bio-Vet contingent consideration. The total Dividend was lifted 11% to 12.50p per share, including a final of 8.90p paid on 24 July 2026. Regionally, the Americas grew 58%, or 20% like-for-like, with US sales reaching £10.7m; Asia grew 22% like-for-like; Europe rose 10%; and IMEA fell 10%, although Indian sales doubled.

The outcome beat the consensus of £45.5m revenue and £8.2m adjusted EBITDA flagged in the 19 January 2026 trading statement. At 535p, the shares trade at roughly 13.5 times FY2025 diluted adjusted EPS, and the 12.50p dividend equates to a trailing Yield of about 2.3%.

What could drive the stock next?

The immediate catalyst is the interim results for the six months to 30 June 2026, scheduled for 9 September 2026. The comparative is demanding: H1 2025 revenue was £22.7m, adjusted EBITDA £4.1m and profit before tax £3.4m, on a 51.4% gross margin. Evidence that margins have held at H2 2025 levels and that sales remain on track for the £50.3m consensus would support the growth story.

Beyond that, watch North American progress under the combined Anpario and Bio-Vet structure, international rollout of QuadriCal, and early traction for AmpLIPhy. A sustained Middle East recovery and continued expansion in India could reverse 2025's IMEA decline.

Capital allocation is another lever. The £3.0m buyback used only part of the cash pile and Bio-Vet shows the board is willing to buy growth. Further buybacks, a higher dividend or another acquisition are all plausible, though none has been announced.

Risks investors should watch

Anpario's markets depend on the Economics of livestock production, which swing with feed grain prices, meat Demand and disease outbreaks. Raw-material inflation has already hit acid-based products, and the company is monitoring the conflict involving Iran for its impact on logistics. Passing costs on relies on customers accepting price rises, which is never guaranteed.

Currency is a persistent Factor for a UK exporter earning most of its revenue overseas. The IMEA decline in 2025 shows how quickly a region can turn. With a Market Capitalisation near £107m, AIM Liquidity can be thin and price moves exaggerated. The board is also short a non-executive director and needs a new remuneration committee chair. Finally, with the company guiding to consensus rather than above it, any shortfall at the interims could be punished.

Outlook

Anpario enters the second half of 2026 with a net cash balance sheet, a record year behind it and management commentary that has so far pointed to continuation rather than deceleration. The 9 September interim results are the next hard data point: look for like-for-like growth, a gross margin around 50%, and confirmation that consensus remains intact.

Whether ANP is a genuine sleeper depends on how much of the 2025 improvement proves structural. The consensus figures the company cites imply slower growth in 2026 than in 2025, so the shares are likely to be judged on delivery against those numbers and on how the board redeploys its cash.